160 related articles for article (PubMed ID: 31393171)
1. Efficacy and safety of lenvatinib in an elderly patient with metastatic papillary thyroid carcinoma and cardiological comorbidity: a case report.
Latorre A; Fioretti AM; Giotta F; Lorusso V
Future Oncol; 2019 Aug; 15(24s):27-33. PubMed ID: 31393171
[TBL] [Abstract][Full Text] [Related]
2. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).
Wirth LJ; Tahara M; Robinson B; Francis S; Brose MS; Habra MA; Newbold K; Kiyota N; Dutcus CE; Mathias E; Guo M; Sherman SI; Schlumberger M
Cancer; 2018 Jun; 124(11):2365-2372. PubMed ID: 29656442
[TBL] [Abstract][Full Text] [Related]
3. Response to Lenvatinib in Children with Papillary Thyroid Carcinoma.
Mahajan P; Dawrant J; Kheradpour A; Quintanilla NM; Lopez ME; Orth RC; Athanassaki I; Venkatramani R
Thyroid; 2018 Nov; 28(11):1450-1454. PubMed ID: 30226445
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment switch from lenvatinib to sorafenib in a patient with radioactive iodine-refractory differentiated thyroid cancer intolerant to lenvatinib due to severe proteinuria.
Goto H; Kiyota N; Otsuki N; Imamura Y; Chayahara N; Suto H; Nagatani Y; Toyoda M; Mukohara T; Nibu KI; Kasahara T; Ito Y; Miya A; Hirokawa M; Miyauchi A; Minami H
Auris Nasus Larynx; 2018 Dec; 45(6):1249-1252. PubMed ID: 29779695
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy of lenvatinib for recurrent papillary thyroid carcinoma after multimodal treatment and management of complications: a case report.
Tori M; Shimo T
BMC Cancer; 2018 Jun; 18(1):698. PubMed ID: 29954369
[TBL] [Abstract][Full Text] [Related]
6. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
7. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer.
Tahara M; Brose MS; Wirth LJ; Suzuki T; Miyagishi H; Fujino K; Dutcus CE; Gianoukakis A
Eur J Cancer; 2019 Jan; 106():61-68. PubMed ID: 30471649
[TBL] [Abstract][Full Text] [Related]
8. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Schlumberger M; Tahara M; Wirth LJ; Robinson B; Brose MS; Elisei R; Habra MA; Newbold K; Shah MH; Hoff AO; Gianoukakis AG; Kiyota N; Taylor MH; Kim SB; Krzyzanowska MK; Dutcus CE; de las Heras B; Zhu J; Sherman SI
N Engl J Med; 2015 Feb; 372(7):621-30. PubMed ID: 25671254
[TBL] [Abstract][Full Text] [Related]
9. Drug safety evaluation of lenvatinib for thyroid cancer.
Krajewska J; Kukulska A; Jarzab B
Expert Opin Drug Saf; 2015; 14(12):1935-43. PubMed ID: 26484847
[TBL] [Abstract][Full Text] [Related]
10. Long-term disease control and high clinical benefit in a patient with advanced thyroid cancer treated with lenvatinib.
Muratori L; Sperone P; Scagliotti GV
Future Oncol; 2019 Aug; 15(24s):3-6. PubMed ID: 31385526
[TBL] [Abstract][Full Text] [Related]
11. Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial.
Brose MS; Worden FP; Newbold KL; Guo M; Hurria A
J Clin Oncol; 2017 Aug; 35(23):2692-2699. PubMed ID: 28613956
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the QTc interval during lenvatinib treatment in radioiodine-refractory differentiated thyroid cancer: reports from the real-life clinical practice.
Marina M; Serra MF; Rio PD; Ceresini G
Future Oncol; 2019 Aug; 15(24s):7-12. PubMed ID: 31418590
[TBL] [Abstract][Full Text] [Related]
13. Gastrointestinal perforation related to lenvatinib, an anti-angiogenic inhibitor that targets multiple receptor tyrosine kinases, in a patient with metastatic thyroid cancer.
Date E; Okamoto K; Fumita S; Kaneda H
Invest New Drugs; 2018 Apr; 36(2):350-353. PubMed ID: 29018997
[TBL] [Abstract][Full Text] [Related]
14. Embolization of iliac metastasis during lenvatinib treatment in patient with advanced Hürthle cell thyroid carcinoma.
Rodia R; Marini S; Pani F; Boi F; Mariotti S
Future Oncol; 2019 Aug; 15(24s):35-40. PubMed ID: 31385535
[TBL] [Abstract][Full Text] [Related]
15. Lenvatinib - A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer.
Hewett Y; Ghimire S; Farooqi B; Shah BK
J Oncol Pharm Pract; 2018 Jan; 24(1):28-32. PubMed ID: 27856921
[TBL] [Abstract][Full Text] [Related]
16. Exposure-response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodine-refractory differentiated thyroid cancer.
Hayato S; Shumaker R; Ferry J; Binder T; Dutcus CE; Hussein Z
Cancer Chemother Pharmacol; 2018 Dec; 82(6):971-978. PubMed ID: 30244318
[TBL] [Abstract][Full Text] [Related]
17. Lenvatinib, an oral multi-kinases inhibitor, -associated hypertension: Potential role of vascular endothelial dysfunction.
Sueta D; Suyama K; Sueta A; Tabata N; Yamashita T; Tomiguchi M; Takeshita T; Yamamoto-Ibusuki M; Yamamoto E; Izumiya Y; Kaikita K; Yamamoto Y; Hokimoto S; Iwase H; Tsujita K
Atherosclerosis; 2017 May; 260():116-120. PubMed ID: 28390289
[TBL] [Abstract][Full Text] [Related]
18. Successful recovery from a subclavicular ulcer caused by lenvatinib for thyroid cancer: a case report.
Kitamura M; Hayashi T; Suzuki C; Hirano S; Tateya I; Kishimoto Y; Omori K
World J Surg Oncol; 2017 Jan; 15(1):24. PubMed ID: 28088233
[TBL] [Abstract][Full Text] [Related]
19. A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.
Takahashi S; Kiyota N; Yamazaki T; Chayahara N; Nakano K; Inagaki L; Toda K; Enokida T; Minami H; Imamura Y; Fukuda N; Sasaki T; Suzuki T; Ikezawa H; Dutcus CE; Tahara M
Future Oncol; 2019 Mar; 15(7):717-726. PubMed ID: 30638399
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
